AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma

RecruitingNAAges 18 Years - anyAllWashington University School of Medicine
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

This clinical study to evaluate sonobiopsy is significant because sonobiopsy will fundamentally enhance the clinician's insight into the molecular features of an intracranial lesion to tailor treatment approaches and optimize outcomes. In addition to the standard diagnostics of anatomic imaging and surgical histology, sonobiopsy has the potential to become the third pillar for brain tumor management by radically advancing the ability to easily and regularly acquire tumor genetic and molecular signatures. This enhanced capability will have a dramatic impact on patient survival and quality of life.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Must be newly diagnosed with a lesion in the brain with imaging characteristics consistent with glioblastoma multiforme. Scan must have occurred no more than 28 days prior to enrollment. * Lesion must be \> 3 cm in maximal dimension on MRI. * Lesion must be in the supratentorial space within 5 cm of the cortical surface. * Lesion must be gadolinium enhancing. * Low grade tumors and metastatic tumors * Recurrent brain tumors and/or radiation necrosis * Must be planning to undergo surgical resection of the tumor. * Must be at least 18 years old. * Patients with recurrent GBM who are planning to undergo surgical resection or laser ablation of the recurrent tumor. Recurrence must be confirmed on MRI performed no more than 28 days prior to enrollment. Exclusion Criteria: * Contraindication to MRI. * Previous cranial surgery. * Previous history of cancer and/or cancer treatments. * Coagulopathy within 14 days of enrollment defined as PT/PTT outside of normal parameters and platelets \< 100,000/mcL. * Physical skull defect of any kind. * Ferrous material in the scalp or skull. * Scalp or skin disease that limits contact with the ultrasound probe. * Enrolled in another clinical trial where intervention is administered prior to surgery. * Known hypersensitivity to polyethylene glycol. * Known unstable cardiopulmonary condition (e.g. acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, serious ventricular arrhythmias).
๐Ÿ’Š

What it tests

  • Sonobiopsy
  • Research blood
  • Cancer Personalized Profiling
  • Definityยฎ
๐Ÿ“

Where

1 site
Washington University School of Medicine
St Louis, United States
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy